Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen’s US Amjevita Sales Slow While Other Growth Drivers Deliver

Executive Summary

Sales of the Humira biosimilar increased double digits globally year over year, but declined 63% in the US versus Q1 due to inventory stockpiling.

You may also be interested in...



CVS Launches Cordavis To Make US Biosimilars More Accessible, Affordable

CVS Health’s new subsidiary Cordavis will help manufacturers produce and/or commercialize biosimilars with the aim of reducing overall drug costs while improving access to and affordability of medicines.

AbbVie Hails Humira’s Resistance To US Competition

As the firm reported Q2 results, AbbVie management offered some insights into how Humira is standing up against US biosimilar adalimumab competition a little better than expected.

Fresh Wave Of Adalimumab Biosimilars Hits US

As launch dates arrive under settlement agreements with Humira originator AbbVie, multiple firms have introduced adalimumab biosimilars in the US, confirming launch and pricing details – with one biosimilar following in the footsteps of Coherus by announcing an 85% discount to the originator.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel